DDInter1917 DDInter1376
Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types. On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Vandetanib {u} (Compound) resembles {v} (Compound) Erlotinib
Vandetanib {u} (Compound) treats {v} (Disease) thyroid cancer
Vandetanib {u} (Compound) binds {v} (Gene) FMO1
Vandetanib {u} (Compound) is included by {v} (Pharmacologic Class) Protein Kinase Inhibitors
Vandetanib {u} (Compound) causes {v} (Side Effect) Blood creatinine increased
Vandetanib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Naloxegol
Vandetanib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Esomeprazole
Vandetanib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vilanterol
Vandetanib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Phenytoin
Vandetanib {u} may lead to a major life threatening interaction when taken with {v} Lefamulin
Vandetanib (Compound) resembles Erlotinib (Compound)
Vandetanib (Compound) treats thyroid cancer (Disease)
Vandetanib (Compound) binds FMO1 (Gene)
Vandetanib (Compound) is included by Protein Kinase Inhibitors (Pharmacologic Class)
Vandetanib (Compound) causes Blood creatinine increased (Side Effect)
Vandetanib may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Vandetanib may cause a minor interaction that can limit clinical effects when taken with Esomeprazole
Vandetanib may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Vandetanib may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin
Vandetanib may lead to a major life threatening interaction when taken with Lefamulin